Get the Stockscreener App
111.12
2.40%
2.60
Monopar Therapeutics Inc stock is traded at $111.12, with a volume of 265.22K.
It is up +2.40% in the last 24 hours and up +72.57% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
See More
Previous Close:
$108.52
Open:
$106.61
24h Volume:
265.22K
Relative Volume:
1.48
Market Cap:
$744.40M
Revenue:
-
Net Income/Loss:
$-14.99M
P/E Ratio:
-53.77
EPS:
-2.0665
Net Cash Flow:
$-10.01M
1W Performance:
+4.24%
1M Performance:
+72.57%
6M Performance:
+58.74%
1Y Performance:
+135.17%
1-Day Range:
$104.00
$111.94
1-Week Range:
$97.93
$111.94
52-Week Range:
$29.18
$112.57
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
111.12 | 726.98M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Morgan Stanley | Overweight |
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy) - Seeking Alpha
Cantor Fitzgerald reiterates Monopar stock Overweight rating at $109 By Investing.com - Investing.com South Africa
Monopar Therapeutics stock trades near $98.20–$111.48 range as buyer strength dominates session - Traders Union
Will Monopar Therapeutics stock regain momentum as buyers support the ongoing rally? - Traders Union
Price to sales forward of Monopar Therapeutics Inc – DUS:1IY0 - TradingView
Monopar Therapeutics stock drops almost 4% after earnings beat followed by downgrade to 'sell' - Traders Union
MNPR Q1 2026 Earnings: EPS Beats Estimates by 46% as Pipeline AdvancesEarnings Acceleration Picks - dars.gov.et
(MNPR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MNPR (MNPR): Arthur Klausner files Form 144/A to sell 5,000 shares - Stock Titan
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT - RTTNews
Monopar Therapeutics shares gain about 9.5% after immediate support holds above $100.45 - Traders Union
What's behind Monopar Therapeutics's latest 11.6% stock surge? - Traders Union
Form 144 Monopar Therapeutics Inc. For: 7 July By Investing.com - Investing.com Nigeria
[144] Monopar Therapeutics SEC Filing - Stock Titan
MNPR stock. Monopar Therapeutics stays tied to its clinical pipeline. - ad-hoc-news.de
Enterprise value to EBIT forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Monopar Therapeutics: ALXN1840's Bull Case Has Improved (NASDAQ:MNPR) - Seeking Alpha
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Monopar Therapeutics (MNPR) CFO nets shares from RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) CEO nets shares after RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) COO gains stock via RSU vesting and tax withholding - Stock Titan
Liquidity Mapping Around (MNPR) Price Events - Stock Traders Daily
Monopar Therapeutics price target raised to $117 from $104 at BTIG - TipRanks
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $117 - Moomoo
MNPR Q1 2026 Earnings: Significant EPS Beat Highlights Progress in Clinical PipelineDiluted EPS Report - dars.gov.et
Form 4 Monopar Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria
MNPR Maintained by BTIG -- Price Target Raised to $117 - GuruFocus
Monopar Therapeutics (MNPR) director granted 1,284 stock options - Stock Titan
Monopar Therapeutics (MNPR) director Nicole Sweeny files initial Form 3 - Stock Titan
Monopar gets rare pediatric disease tag for Wilson treatment - Investing.com UK
Monopar Therapeutics (MNPR) Receives FDA Rare Pediatric Disease Designation - GuruFocus
Monopar Therapeutics Inc. Granted FDA Rare Pediatric Disease Designation – Official SEC 8-K Filing June 30, 2026 - Minichart
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $117 - Moomoo
Monopar Wins FDA Rare Pediatric Disease Designation - TipRanks
Monopar stock jumps after FDA rare pediatric disease tag By Investing.com - Investing.com India
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease - The Manila Times
FDA grants Rare Pediatric Disease designation to Monopar (MNPR) Wilson disease drug ALXN1840 - Stock Titan
FDA rare pediatric disease tag could speed ALXN1840’s path for Wilson disease - Stock Titan
BTIG raises Monopar Therapeutics price target on regulatory outlook - Investing.com
BTIG raises Monopar Therapeutics price target on regulatory outlook By Investing.com - Investing.com Canada
+8.47% for Monopar Therapeutics stock as buyers push price above key averages - Traders Union
Monopar Therapeutics Inc Actuals & Estimates (NASDAQ:MNPR) - TradingView
H.C. Wainwright reiterates Monopar stock rating on trial data By Investing.com - Investing.com India
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - Moomoo
Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 2000 Value Benchmark - marketscreener.com
H.C. Wainwright reiterates Monopar stock rating on trial data - Investing.com UK
Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell Microcap Value Benchmark Index - marketscreener.com
MNPR Reiterates by HC Wainwright & Co. -- Price Target Maintained at $105 - GuruFocus
Monopar Therapeutics Insiders Make Handsome Sum Selling Stock At US$67.15 Per Share - simplywall.st
Price to earnings forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Price to book forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vu Quan Anh | Chief Financial Officer |
Dec 26 '25 |
Buy |
69.95 |
1,500 |
104,925 |
1,500 |
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):